Aroa is unlocking regenerative healing, accessability and affordabilityFind out more
Reinforced Bioscaffolds combine the best of biologics and synthetics to address the current shortcomings in surgical ventral hernia repair solutions. Read more about Reinforced Bioscaffolds on the TelaBio website.
Find out more
Our focus is delivering better healing, everyday, everywhere for everybody. We strive to make a meaningful impact for patients, surgeons and clinicians. We deliver high quality, simple to…Find out more
Auckland, NZ. Aroa Biosurgery has posted a modest profit for the FY18/19 year, a first for the Auckland-based, privately held tissue-regeneration company since its formation 10 years ago.
Chief Executive Brian Ward said the first-time push into profit would be welcome news for the company’s tight and supportive family of investors. It was achieved off the back of 118% revenue growth to $24.2 million
1,000 cm2 device now commercially available in the U.S. rounds out portfolio of surgical mesh for full range of complex surgical procedures
MALVERN, P.A. and Auckland NZ– January 10, 2019 – TELA Bio®, Inc. and Aroa Biosurgery, the joint developers of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market large sizes of OviTex RBS. The OviTex Permanent product line is now commercially available in United States from TELA Bio in sizes up to 25x40 cm (1,000 cm2), which is a 150% surface area increase over currently available devices.
Early outcomes from post-market clinical study presented at Abdominal Wall Reconstruction Conference in Washington, DC.
MALVERN, Pa., June 7, 2018 /PRNewswire/ -- TELA Bio®, Inc., a surgical reconstruction company leading the development and commercialization of OviTex® Reinforced BioScaffolds (RBSs) for soft tissue repair, today announced that early outcomes from the company's post-market BRAVO (BioScaffold Reconstruction of Abdominal wall and Ventral hernia defects with Open or laparoscopic repair) study evaluating OviTex 1S Permanent for the treatment of ventral hernias are being presented at the 2018 Abdominal Wall Reconstruction Conference taking place June 7 – 9 at the Grand Hyatt Washington in Washington, DC.